Platelet Disorders

The 67th ASH Annual Meeting and Exposition brought over 30,000+ attendees, 5,000+ novel abstracts and 275+ exhibitors corporate supporters, academic leaders and patient-advocacy groups. The meeting highlighted innovations ranging from novel agents to real-world evidence and patient-centred care. In this article, hear from the experts on the key breakthroughs and clinical insights set to shape the future of haematology practice.

Learn more about the six highly anticipated late-breaking abstracts at ASH 2025. From in-vivo CAR-T technology and novel ITP strategies to genomic diagnostics and pragmatic perioperative trials. These data showcase fresh, innovative research, potential practice shifts and early signals that we will all want to follow closely.

The 67th ASH Annual Meeting and Exposition spotlighted many pivotal trial results across non-malignant haematology including immune thrombocytopenia, bleeding disorders, iron deficiency, von Willebrand disease, cancer-associated hematologic complications and more. We break down some of the most important abstracts presented, and what this might mean for future clinical practice.

Abigail Ajanel Gomez, a PhD student and recipient of the ASH Graduate Hematology Award, is advancing understanding of platelet activation and thrombosis. Her work highlights the therapeutic potential of targeting mitochondrial calcium flux. A dedicated mentor, she is committed to fostering curiosity and critical thinking in the next generation of scientists.

The European Hematology Association (EHA) has released its official EHA Perspectives in Hematology reports from the 2025 Annual Congress in Milan, now available in two separate editions covering malignant and non-malignant hematology. Following strong interest in the 2024 pilot report, this expanded format offers deeper insights into scientific and clinical advances across the field.

INCA33989, a mutant CALR-specific antibody, showed an 80% platelet normalization rate and no dose-limiting toxicities in early-phase trials for essential thrombocythemia. Dr. John Mascarenas highlights the agent’s potential as a disease-modifying therapy, with reductions in mutant CALR burden and strong tolerability—marking a significant step forward in ET treatment.

As touchHAEMATOLOGY approaches 20 years of providing education for busy haematologists, we are looking to the future—and it certainly looks bright!

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.

What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.